Primary Autoimmune Hemolytic Anemia Due To Warm Reactive Autoantibodies: A Rare Case Report
PDF Downloads : 64    VIEW PDF

Keywords

Autoimmune hemolytic anemia (AIHA)
Direct Coomb’s Test (DCT)
Warm reactive autoantibody
Blood transfusion

How to Cite

Shinde, D. A., Shinde, D. S., Dr. Sushrut Kumar, Kothari, D. R., & Mhaske, D. S. . (2021). Primary Autoimmune Hemolytic Anemia Due To Warm Reactive Autoantibodies: A Rare Case Report. VIMS Health Science Journal , 8(3), 119-123. https://doi.org/10.46858/vimshsj.8307

Abstract

Autoimmune hemolytic anemia (AIHA) is an acquired form of hemolytic anemia in which autoantibodies target red blood cell (RBC) membrane antigens, inducing cell rupture (lysis).  It affects both pediatric and adult populations, although its presentation in childhood is relatively rare, with the annual incidence estimated to be approximately 0.8 per 100,000 individuals under 18 years old [3]. Here we report  one such a rare case of autoimmune hemolytic anemia due to primary warm reactive autoantibodies in a 3 year old female child. As there was presence of hemolysis in peripheral blood smear &  other investigations also,  Direct coomb’s test was done & it came out to be positive which was suggestive of autoimmune hemolytic anemia, as following lab reports are suggestive of continuous destruction of RBC & after introduction of steroids parameters of  hemolysis came out to be normal suggestive of warm reactive autoantibodies type of AIHA. Clinically also patient improved & her urine colour also became normal after when prednisolone started. Patient also did not have any features of secondary causes of warm autoantibody like Systemic lupus erythematous, immunodeficiency disorders, ulcerative colitis & lymphoproliferative disorders so it was considered primary or idiopathic. W-AIHA tends to have a chronic course and is not expected to subside without treatment. It can be a fatal disease, with a mortality rate of up to 4% in children, either because of the acuity of the presentation or because of being refractory to treatment and requiring multiple lines of therapy with frequently associated toxicity [14]. Fortunately our patient responded to steroid therapy.

https://doi.org/10.46858/vimshsj.8307
PDF Downloads : 64    VIEW PDF

References

Hill, Q.A.; Hill, A.; Berentsen, S. Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019, 3, 1897–1906. [CrossRef] [PubMed]

Michel, M. Classification and therapeutic approaches in autoimmune hemolytic anemia: An update. Expert Rev. Hematol. 2011, 4, 607–618. [CrossRef] [PubMed]

Aladjidi, N.; Jutand, M.A.; Beaubois, C.; Fernandes, H.; Jeanpetit, J.; Coureau, G.; Gilleron, V.; Kostrzewa, A.; Lauroua, P.; Jeanne, M.; et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr. Blood Cancer 2017, 64, e26683. [CrossRef] [PubMed]

Aladjidi, N.; Leverger, G.; Leblanc, T.; Picat, M.Q.; Michel, G.; Bertrand, Y.; Bader-Meunier, B.; Robert, A.; Nelken, B.; Gandemer, V.; et al. New insights into childhood autoimmune hemolytic anemia: A French national observational study of 265 children. Haematologica 2011, 96, 655–663. [CrossRef]

Vaglio, S.; Arista, M.C.; Perrone, M.P.; Tomei, G.; Testi, A.M.; Coluzzi, S.; Girelli, G. Autoimmune hemolytic anemia in childhood: Serologic features in 100 cases. Transfusion 2007, 47, 50–54. [CrossRef]

Sankaran, J.; Rodriguez, V.; Jacob, E.K.; Kreuter, J.D.; Go, R.S. Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience. J. Pediatr. Hematol. Oncol. 2016, 38, e120–e124. [CrossRef]

Voulgaridou, A.; Kalfa, T.A. Autoimmune Hemolytic Anemia in the Pediatric Setting. J. Clin. Med. 2021, 10, 216. https://doi.org/ 10.3390/jcm10020216

Gehrs, B.C.; Friedberg, R.C. Autoimmune hemolytic anemia. Am. J. Hematol. 2002, 69, 258–271. [CrossRef]

Kalfa, T.A. Warm antibody autoimmune hemolytic anemia. Hematol. Am. Soc. Hematol. Educ. Program 2016, 2016, 690–697. [CrossRef]

Naithani, R.; Agrawal, N.; Mahapatra, M.; Kumar, R.; Pati, H.P.; Choudhry, V.P. Autoimmune hemolytic anemia in children. Pediatr. Hematol. Oncol. 2007, 24, 309–315. [CrossRef]

Segel, G.B.; Lichtman, M.A. Direct antiglobulin (“Coombs”) test-negative autoimmune hemolytic anemia: A review. Blood Cells Mol. Dis. 2014, 52, 152–160. [CrossRef]

Branstetter, C.N.; Hankins, J.S.; Moreau, D.; Nottage, K.A. Severe Autoimmune Hemolytic Anemia in an Infant Caused by Warm-reactive IGM and IGA Autoantibodies: A Case Report and Review of the Literature. J. Pediatr. Hematol. Oncol. 2015, 37, 468–471. [CrossRef] [PubMed]

Berentsen, S.; Hill, A.; Hill, Q.A.; Tvedt, T.H.A.; Michel, M. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther. Adv. Hematol. 2019, 10. [CrossRef] [PubMed]

Kanellopoulou, T. Autoimmune hemolytic anemia in solid organ transplantation-The role of immunosuppression. Clin. Transplant. 2017, 31, e13031. [CrossRef]

Johnson, S.T.; Fueger, J.T.; Gottschall, J.L. One center’s experience: The serology and drugs associated with drug-induced immune hemolytic anemia–a new paradigm. Transfusion 2007, 47, 697–702. [CrossRef]

Teachey, D.T.; Lambert, M.P. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr. Clin. N. Am. 2013, 60, 1489–1511. [CrossRef]

Ozsoylu, F. Megadose methylprednisolone for the treatment of patients with Evans syndrome. Pediatr. Hematol. Oncol. 2004, 21, 739–740. [CrossRef] [PubMed]

Zanella, A.; Barcellini, W. Treatment of autoimmune hemolytic anemias. Haematologica 2014, 99, 1547–1554. [CrossRef]

Petz, L.D. A physician’s guide to transfusion in autoimmune haemolytic anaemia. Br. J. Haematol. 2004, 124, 712–716. [CrossRef]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2021 Dr. Abhijit Shinde, Dr. Sonal Shinde, Dr. Sushrut Kumar, Dr. Ramesh Kothari, Dr. Sneha Mhaske

Downloads

Download data is not yet available.